Dulaglutide
Trulicity
A weekly GLP-1 approved for diabetes and never for obesity, with the unusual distinction of proving cardiovascular benefit in people who had not yet had a cardiac event.
FDA-approved
FDA-approved in September 2014 for type 2 diabetes, and later to reduce major adverse cardiovascular events. Not approved for weight management at any dose.
What it is
Dulaglutide is a GLP-1 agonist fused to a modified antibody fragment. That fusion is the design: attaching the peptide to an IgG4 Fc region borrows the antibody's slow clearance and stretches the half-life to roughly five days, which is what makes weekly dosing possible.
It arrived in 2014, the same era as the other weekly incretins, and it has been widely prescribed for type 2 diabetes ever since. What it has never been is an obesity drug.
What the evidence shows
REWIND is the trial that distinguishes it. Published in the Lancet in 2019, it followed nearly ten thousand people with type 2 diabetes over a median of more than five years and found a significant reduction in major adverse cardiovascular events.
The unusual part is who was enrolled. Most cardiovascular outcome trials in this space recruit people who have already had a heart attack or stroke, which makes the finding one about secondary prevention. REWIND enrolled a majority who had not, so the benefit extended to primary prevention. That earned an FDA indication no other drug in the class held at the time.
On weight, dulaglutide is modest. It produces a few kilograms at the higher doses, enough to be a welcome side effect in diabetes management and nowhere near enough to compete with semaglutide or tirzepatide. Novo and Lilly both pursued obesity indications with different molecules, which tells you what they concluded about this one.
Why it appears here at all
People arrive at dulaglutide sideways: it is what their doctor already prescribes for diabetes, and they want to know how it compares to the drug they have been reading about. The honest answer is that it is a good diabetes drug with a real cardiovascular story and a weak weight story, and that switching for weight loss reasons means switching molecules, not doses.
Practical notes
- The 3 mg and 4.5 mg doses came later. The AWARD-11 programme added them in 2020. They improve glycaemic control and weight modestly over 1.5 mg, and increase gastrointestinal side effects correspondingly.
- Weekly dosing forgives more than daily does. A missed dose can be taken if at least three days remain before the next scheduled one, which is a meaningful practical advantage over liraglutide.
- Do not stack it with another incretin. Every compound in this class hits the same receptor. Combining two produces the side effects of both and the benefit of roughly one.
Side effects and warning signs
Commonly reported
- Nausea, typically worst after a dose increase
- Diarrhoea and vomiting
- Abdominal pain
- Reduced appetite
- Injection-site reactions
Stop and get medical help
- Personal or family history of medullary thyroid carcinoma or MEN2, a boxed contraindication across the class
- Severe persistent abdominal pain radiating to the back
- Rapidly worsening diabetic retinopathy during sharp glycaemic improvement
Sources
From the community
Discussion for this compound concentrates in r/diabetes_t2 and r/Semaglutide.
No threads cached yet.
Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.